Delta Investment Management LLC Makes New $280,000 Investment in Boston Scientific Corporation $BSX

Key Points

• Delta Investment Management LLC acquired a new stake in Boston Scientific Corporation, purchasing 2,773 shares valued at approximately $280,000 in the 1st quarter.
• Notable institutional investors, including GAMMA Investing LLC and Vanguard Group Inc., have significantly increased their stakes in Boston Scientific, indicating strong investor confidence in the company.
• Boston Scientific reported better-than-expected quarterly earnings with $0.75 EPS, surpassing analysts' estimates and showing a 22.8% year-over-year revenue increase.

Delta Investment Management LLC acquired a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,773 shares of the medical equipment provider's stock, valued at approximately $280,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in BSX. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 1,625.0% in the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 260 shares during the period. Investment Management Corp VA ADV acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $25,000. Sunbeam Capital Management LLC acquired a new stake in shares of Boston Scientific in the fourth quarter valued at about $26,000. Y.D. More Investments Ltd acquired a new stake in shares of Boston Scientific in the first quarter valued at about $27,000. Finally, Ameriflex Group Inc. acquired a new position in Boston Scientific during the fourth quarter worth about $31,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Insider Activity

In related news, CEO Michael F. Mahoney sold 164,443 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the completion of the transaction, the chief executive officer owned 1,476,882 shares of the company's stock, valued at approximately $153,137,894.58. This represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction that occurred on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 345,029 shares of company stock valued at $35,976,603 in the last ninety days. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Down 0.2%

Shares of NYSE BSX traded down $0.19 during midday trading on Friday, reaching $105.56. 4,066,860 shares of the stock were exchanged, compared to its average volume of 5,967,270. The company has a market capitalization of $156.41 billion, a P/E ratio of 62.83, a P/E/G ratio of 2.54 and a beta of 0.66. Boston Scientific Corporation has a 52-week low of $79.53 and a 52-week high of $108.94. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a 50 day moving average price of $104.53 and a 200-day moving average price of $102.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm posted $0.62 earnings per share. The company's quarterly revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on BSX shares. Morgan Stanley increased their price target on shares of Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research report on Friday, May 16th. Royal Bank Of Canada reiterated an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Leerink Partners initiated coverage on Boston Scientific in a research report on Monday, June 16th. They set an "outperform" rating and a $118.00 price target for the company. Raymond James Financial raised their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 24th. Finally, Oppenheimer raised their price target on Boston Scientific from $110.00 to $118.00 and gave the stock a "market perform" rating in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.